Its not poor accounting practises at all. Using accrual accounting the $15M is "un-earned or deferred" revenue until the company delivers a good or service to Amgen. It has to be treated as a pre-payment on the balance sheet. Our one-off upfronts and milestones from other companies are similarly treated this way.
As for delisting from NASDAQ, worst case scenario, cant they simply do a reverse split? Consolidate shares 10 for 1 to get the share price over $1.00 UNIS? Worst case scenario.
UNS Price at posting:
22.0¢ Sentiment: Hold Disclosure: Held
